Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Suffers Nexavar Setback As India's Supreme Court Dismisses Linkage of Patent With Generic Marketing Approval

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - German pharma and healthcare firm Bayer suffered yet another jolt in its two-year attempt to establish a patent linkage to registration of generic versions of its kidney and liver cancer drug Nexavar (sorafenib) as India's Supreme Court dismissed the company's pleas and referred the case back to the Delhi High Court
Advertisement

Related Content

Bayer Challenges Nexavar Compulsory License To Natco; Says It Endangers Pharma Research
Indian Compulsory License Debate Enters New Phase With Push From Local Pharma Natco
Indian Compulsory License Debate Enters New Phase With Push From Local Pharma Natco
Indian Firms Must Be In Indian Hands, Says Government Paper; Highlights Threats to Compulsory Licensing And Drug Pricing
Indian Court Nixes Bayer's Nexavar Patent Plea; Cipla Allowed To Market Generic Versions
Indian Court Nixes Bayer's Nexavar Patent Plea; Cipla Allowed To Market Generic Versions
Advertisement
UsernamePublicRestriction

Register

SC073841

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel